15.27
0.28 (1.87%)
| Penutupan Terdahulu | 14.99 |
| Buka | 14.95 |
| Jumlah Dagangan | 50,467 |
| Purata Dagangan (3B) | 228,933 |
| Modal Pasaran | 947,188,928 |
| Harga / Buku (P/B) | 3.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -0.790 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.21% |
| Nisbah Semasa (MRQ) | 29.71 |
| Aliran Tunai Operasi (OCF TTM) | -41.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.93 M |
| Pulangan Atas Aset (ROA TTM) | -11.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | GH Research PLC | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.63 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.88% |
| % Dimiliki oleh Institusi | 68.90% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Troluce Capital Advisors Llc | 31 Dec 2025 | 373,212 |
| Squadron Capital Management Llc | 31 Dec 2025 | 315,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (HC Wainwright & Co., 358.42%) | Beli |
| Median | 41.00 (168.50%) | |
| Rendah | 32.00 (Needham, 109.56%) | Beli |
| Purata | 46.00 (201.24%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 16.15 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 06 Mar 2026 | 42.00 (175.05%) | Beli | 15.93 |
| Needham | 06 Mar 2026 | 32.00 (109.56%) | Beli | 15.93 |
| HC Wainwright & Co. | 02 Mar 2026 | 70.00 (358.42%) | Beli | 16.01 |
| RBC Capital | 23 Jan 2026 | 40.00 (161.95%) | Beli | 16.73 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |